Nephrology Times
@nephtimes.bsky.social
Delivering the latest news in nephrological treatments and technologies with the goal of better informing care decisions and improving patient outcomes
Happy Thanksgiving to our US readers.
(pikisuperstar / Freepik)
(pikisuperstar / Freepik)
November 27, 2025 at 3:30 PM
Happy Thanksgiving to our US readers.
(pikisuperstar / Freepik)
(pikisuperstar / Freepik)
👓 WATCH NOW: Richard Knight, MD, talks about ongoing challenges in kidney transplantation and how emerging tools and strategic policies might help. #kidneytransplant #transplantation #nephrology #nephsky www.docwirenews.com/post/the-kid...
The Kidney Transplant Landscape | Docwire News
Richard Knight, MD, discusses challenges in human and pig kidney transplantation and how machine learning and other advances can help.
www.docwirenews.com
November 25, 2025 at 7:10 PM
👓 WATCH NOW: Richard Knight, MD, talks about ongoing challenges in kidney transplantation and how emerging tools and strategic policies might help. #kidneytransplant #transplantation #nephrology #nephsky www.docwirenews.com/post/the-kid...
👀 WATCH NOW: Joel Topf @kidneyboy.bsky.social caught up with Rajiv Agarwal at #KidneyWk in Houston, where the latter presented CONFIDENCE findings on implementation of finerenone and empagliflozin. #nephrology #nephsky #kidneydisease #hyperkalemia #sglt2 www.docwirenews.com/post/hyperka...
Hyperkalemia With Empagliflozin and Finerenone | Docwire News
Joel Topf, MD, interviewed Rajiv Agarwal, MBBS, about an implementation analysis of CONFIDENCE findings on hyperkalemia with finerenone and empagliflozin in chronic kidney disease.
www.docwirenews.com
November 21, 2025 at 2:52 PM
👀 WATCH NOW: Joel Topf @kidneyboy.bsky.social caught up with Rajiv Agarwal at #KidneyWk in Houston, where the latter presented CONFIDENCE findings on implementation of finerenone and empagliflozin. #nephrology #nephsky #kidneydisease #hyperkalemia #sglt2 www.docwirenews.com/post/hyperka...
Another #KidneyWk, another showcase for #IgAN therapies. Joel Topf @kidneyboy.bsky.social spoke with Jonathan Barratt about his trials of mezagitamab and atacicept. #nephsky #nephrology #iganephropathy www.docwirenews.com/post/mezagit...
Mezagitamab, Atacicept, and the Rise of IgAN Therapies | Docwire News
Joel Topf, MD, spoke with Jonathan Barratt, PhD, about his Kidney Week presentations on mezagitamab and atacicept and the landscape of IgA nephropathy (IgAN).
www.docwirenews.com
November 20, 2025 at 10:40 PM
Another #KidneyWk, another showcase for #IgAN therapies. Joel Topf @kidneyboy.bsky.social spoke with Jonathan Barratt about his trials of mezagitamab and atacicept. #nephsky #nephrology #iganephropathy www.docwirenews.com/post/mezagit...
Check out 5 of our favorite highlights from ASN #KidneyWk. #nephrology #nephsky www.docwirenews.com/post/5-highl...
5 Highlights from ASN Kidney Week 2025 | Docwire News
ASN Kidney Week included the FINE-ONE type 1 diabetes trial, PISCES trial of fish oil in dialysis, a new research grant, and lectures on public health and renal drug development.
www.docwirenews.com
November 19, 2025 at 8:17 PM
Check out 5 of our favorite highlights from ASN #KidneyWk. #nephrology #nephsky www.docwirenews.com/post/5-highl...
Joel Topf @kidneyboy.bsky.social spoke with Jai Radhakrishnan at #KidneyWk about his late-breaking research poster describing a new analysis of data from the DUPLEX trial of sparsentan in #FSGS. #nephsky #nephrology www.docwirenews.com/post/sparsen...
Sparsentan and the 0.7 g/g Proteinuria Threshold in FSGS | Docwire News
Drs. Joel Topf and Jai Radhakrishnan discuss an analysis of data from the DUPLEX trial of sparsentan in focal segmental glomerulosclerosis (FSGS) and trial end points for FSGS.
www.docwirenews.com
November 18, 2025 at 4:45 PM
Joel Topf @kidneyboy.bsky.social spoke with Jai Radhakrishnan at #KidneyWk about his late-breaking research poster describing a new analysis of data from the DUPLEX trial of sparsentan in #FSGS. #nephsky #nephrology www.docwirenews.com/post/sparsen...
At #KidneyWk, we spoke with Hiddo J. L. Heerspink about the FINE-ONE trial and the first meaningful progress in T1D kidney disease in decades. #nephrology #nephsky #diabetes #kidneydisease www.docwirenews.com/post/trials-...
Trials Update: Finerenone in T1D, Balcinrenone, and More | Docwire News
Joel Topf and Hiddo Heerspink discuss finerenone in type 1 diabetes and kidney disease (FINE-ONE), the MRA balcinrenone, and renal trial end points.
www.docwirenews.com
November 17, 2025 at 2:04 PM
At #KidneyWk, we spoke with Hiddo J. L. Heerspink about the FINE-ONE trial and the first meaningful progress in T1D kidney disease in decades. #nephrology #nephsky #diabetes #kidneydisease www.docwirenews.com/post/trials-...
Our #KidneyWk coverage continues to roll out. Next up is our interview with Vlado Perkovic on the possibility of curing #kidneydisease and his take on the FINE-ONE and ORIGIN-3 trials presented on day 1 of the meeting. #nephrology #nephsky www.docwirenews.com/post/curing-...
Curing Kidney Disease: What’s Changing in DKD and IgAN | Docwire News
At ASN Kidney Week 2025, Drs. Joel Topf and Vlado Perkovic discussed curing kidney disease and high-impact trials in diabetic kidney disease and IgA nephropathy (IgAN).
www.docwirenews.com
November 14, 2025 at 5:59 PM
Our #KidneyWk coverage continues to roll out. Next up is our interview with Vlado Perkovic on the possibility of curing #kidneydisease and his take on the FINE-ONE and ORIGIN-3 trials presented on day 1 of the meeting. #nephrology #nephsky www.docwirenews.com/post/curing-...
ICYMI: KidneyCure, the philanthropic arm of ASN, will invest up to $6M in grants over 3 years to support kidney research. #kidneydisease #research #nephrology
www.docwirenews.com/post/kidneyc...
www.docwirenews.com/post/kidneyc...
KidneyCure Commits $6 Million to Support Researchers Affected by NIH Funding Cuts | Docwire News
KidneyCure, the philanthropic foundation of the American Society of Nephrology (ASN), will invest $6 million in research grants to support kidney researchers affected by NIH cuts.
www.docwirenews.com
November 14, 2025 at 4:15 PM
ICYMI: KidneyCure, the philanthropic arm of ASN, will invest up to $6M in grants over 3 years to support kidney research. #kidneydisease #research #nephrology
www.docwirenews.com/post/kidneyc...
www.docwirenews.com/post/kidneyc...
Don't miss part 2 of #KidneyWk highlights from @kidneyboy.bsky.social and @annagaddy.bsky.social. #nephsky #nephrology www.docwirenews.com/post/asn-kid...
ASN Kidney Week 2025 Day 2 Highlights | Docwire News
Nephrology Times board members Joel Topf, MD, and Anna Gaddy, MD, met at American Society of Nephrology (ASN) Kidney Week 2025 in Houston to discuss day 2's highlights.
www.docwirenews.com
November 13, 2025 at 4:53 PM
Don't miss part 2 of #KidneyWk highlights from @kidneyboy.bsky.social and @annagaddy.bsky.social. #nephsky #nephrology www.docwirenews.com/post/asn-kid...
🚨Attention #KidneyCare professionals!🚨 Registration is OPEN for @kidney.org 2026 Spring Clinical Meetings! Take advantage of early bird discounted rates and explore the latest in clinical research, patient care, and professional development in #nephrology.
Learn More: www.kidney.org/spring-clini...
Learn More: www.kidney.org/spring-clini...
November 13, 2025 at 2:57 PM
🚨Attention #KidneyCare professionals!🚨 Registration is OPEN for @kidney.org 2026 Spring Clinical Meetings! Take advantage of early bird discounted rates and explore the latest in clinical research, patient care, and professional development in #nephrology.
Learn More: www.kidney.org/spring-clini...
Learn More: www.kidney.org/spring-clini...
How would you discuss prognosis in advanced kidney disease with a patient? Five nephrologists share their opinions. #nephrology #nephsky #kidneydisease www.docwirenews.com/post/5-nephr...
5 Nephrologists, 1 Question: Discussing Prognosis in Advanced Kidney Disease | Docwire News
In this recurring section, Nephrology Times asked five nephrologists: How do you discuss prognosis in advanced kidney disease?
www.docwirenews.com
November 12, 2025 at 5:38 PM
How would you discuss prognosis in advanced kidney disease with a patient? Five nephrologists share their opinions. #nephrology #nephsky #kidneydisease www.docwirenews.com/post/5-nephr...
Miss out on #KidneyWk? Catch up with day 1's highlights courtesy of Drs. Joel Topf and Anna Gaddy. @kidneyboy.bsky.social #nephrology #nephsky #kidneydisease
www.docwirenews.com/post/asn-kid...
www.docwirenews.com/post/asn-kid...
ASN Kidney Week 2025 Day 1 Highlights | Docwire News
Nephrology Times board members Joel Topf, MD, and Anna Gaddy, MD, met at American Society of Nephrology (ASN) Kidney Week 2025 in Houston to discuss day 1's highlights.
www.docwirenews.com
November 12, 2025 at 5:09 PM
Miss out on #KidneyWk? Catch up with day 1's highlights courtesy of Drs. Joel Topf and Anna Gaddy. @kidneyboy.bsky.social #nephrology #nephsky #kidneydisease
www.docwirenews.com/post/asn-kid...
www.docwirenews.com/post/asn-kid...
Hey #NephSky: Would you like to contribute your answer to our next "5 Nephrologists, 1 Question" column? The question: What recent research has most changed your approach to managing glomerulonephritis? If you want to answer this or a future question, drop a comment.
November 11, 2025 at 9:55 PM
Hey #NephSky: Would you like to contribute your answer to our next "5 Nephrologists, 1 Question" column? The question: What recent research has most changed your approach to managing glomerulonephritis? If you want to answer this or a future question, drop a comment.
One of the surprises of ASN Kidney Week was the PISCES trial presentation, showing that there may be a simple way to greatly improve CV outcomes in hemodialysis. #kidneywk #nephsky #nephrology #hemodialysis www.docwirenews.com/post/pisces-...
PISCES Fish Oil Data Make a Splash | Docwire News
PISCES trial data presented at Kidney Week 2025 showed that daily fish oil supplements lowered the rate of serious cardiovascular events for patients on maintenance hemodialysis.
www.docwirenews.com
November 11, 2025 at 8:54 PM
One of the surprises of ASN Kidney Week was the PISCES trial presentation, showing that there may be a simple way to greatly improve CV outcomes in hemodialysis. #kidneywk #nephsky #nephrology #hemodialysis www.docwirenews.com/post/pisces-...
Sarah Tolson shares an example of how to challenge claim denials when all avenues involving the payer have been exhausted. #medicalbilling #claims #nephrology #reimbursement www.docwirenews.com/post/when-th...
When the Payer Is the Problem: Building Better Escalation Pathways | Docwire News
In her column, Sarah Tolson examines when and how to escalate a payer dispute beyond the payer itself.
www.docwirenews.com
November 11, 2025 at 5:15 PM
Sarah Tolson shares an example of how to challenge claim denials when all avenues involving the payer have been exhausted. #medicalbilling #claims #nephrology #reimbursement www.docwirenews.com/post/when-th...
Editorial chair Dr. Ajay Singh discusses how removing race from eGFR equations turned conviction into conduct and gave Black transplant candidates fairer access to kidney transplantation. #nephrology #kidneytransplantation #healthequity www.docwirenews.com/post/when-pu...
When Public Policy Makes a Meaningful Difference to Patient Lives | Docwire News
OPTN policies to correct racial inequities, including adopting the race-free equation for estimating glomerular filtration rate, are giving Black kidney transplant candidates hope.
www.docwirenews.com
November 10, 2025 at 4:32 PM
Editorial chair Dr. Ajay Singh discusses how removing race from eGFR equations turned conviction into conduct and gave Black transplant candidates fairer access to kidney transplantation. #nephrology #kidneytransplantation #healthequity www.docwirenews.com/post/when-pu...
WHEW! ASN #KidneyWk wraps up today, kicking off with a talk on xenotransplantation and wrapping up with a special session on the IOTA Model. DON'T FORGET to check our website for more coverage. www.docwirenews.com/conference/a... #nephrology #kidneytransplantation
ASN Kidney Week 2025 | Docwire News
Review highlights from abstracts and presentations at ASN Kidney Week 2025, presented by the American Society of Nephrology, on Nephrology Times
www.docwirenews.com
November 9, 2025 at 1:30 PM
WHEW! ASN #KidneyWk wraps up today, kicking off with a talk on xenotransplantation and wrapping up with a special session on the IOTA Model. DON'T FORGET to check our website for more coverage. www.docwirenews.com/conference/a... #nephrology #kidneytransplantation
✈️ We're heading home from ASN #KidneyWk but can't wait to share more from the event with you. Keep an eye on our website for Dr. Joel Topf's interviews with presenters. @asnkidney.bsky.social @kidneyboy.bsky.social #nephrology www.docwirenews.com/conference/a...
ASN Kidney Week 2025 | Docwire News
Review highlights from abstracts and presentations at ASN Kidney Week 2025, presented by the American Society of Nephrology, on Nephrology Times
www.docwirenews.com
November 8, 2025 at 10:00 PM
✈️ We're heading home from ASN #KidneyWk but can't wait to share more from the event with you. Keep an eye on our website for Dr. Joel Topf's interviews with presenters. @asnkidney.bsky.social @kidneyboy.bsky.social #nephrology www.docwirenews.com/conference/a...
Reposted by Nephrology Times
It’s the last day of #KidneyWk — don’t head home without visiting the ASN Membership Booth! Stop by between 7:30 a.m.–2:30 p.m. CST to renew or join for 2026 and stay connected to ASN resources, opportunities, and the kidney community year-round.
November 8, 2025 at 2:26 PM
It’s the last day of #KidneyWk — don’t head home without visiting the ASN Membership Booth! Stop by between 7:30 a.m.–2:30 p.m. CST to renew or join for 2026 and stay connected to ASN resources, opportunities, and the kidney community year-round.
“I hope I didn’t bring you down,” he said. Judging from the ovation, probably the opposite.
If you're not at the #KidneyWk plenary this morning, you are missing @robcaliff.bsky.social absolutely putting people on notice about the real issues we face in US healthcare. Great speech.
November 8, 2025 at 2:25 PM
“I hope I didn’t bring you down,” he said. Judging from the ovation, probably the opposite.